Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Tilray Brands Inc TLRY

Alternate Symbol(s): T.TLRY

Healthcare Cannabis

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.

NDAQ:TLRY - Post by User

Tilray Brands Inc > Tilray Brands German Market by

<< Previous

Bullboard Posts

Next >>

Comment by Ventura2020on Feb 18, 2024 11:42am

72 Views

Post# 35886647

RE:RE:Tilray Brands German Market by

Maersk wrote: "Unlimited production in country now for Tilray, Aurora and Demecan."

And any other company that wants to grow cannabis in Germany. The goal is to reduce Germany's reliance on imports, and since Cansativa is the sole distributor for German-grown cannabis, it begs the question of how much market share will remain for CC Pharma, or what the overall medical market will be post-legalization.

From the European Cannabis Association:

"As a preliminary assessment, it can be assumed that, while the medicinal cannabis market in Germany might also stagnate or slightly decrease after a potential legalization of cannabis for recreational use, it is certainly not exposed to fluctuations as high as other international markets."